Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2017

27.03.2017 | case report

Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma

verfasst von: MD Sonja Burgstaller, Josef Thaler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80 years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of brentuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organisation of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22. CrossRefPubMed Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organisation of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22. CrossRefPubMed
2.
Zurück zum Zitat Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73. CrossRefPubMedPubMedCentral Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Cuneo A, Castoldi GL. Primary cutaneous CD30 + anaplastic large-cell lymphoma. Atlas Genet Cytogenet Oncol Haematol. 2005;9(3):244–5. Cuneo A, Castoldi GL. Primary cutaneous CD30 + anaplastic large-cell lymphoma. Atlas Genet Cytogenet Oncol Haematol. 2005;9(3):244–5.
4.
Zurück zum Zitat Weng WK, Armstrong R, Arai S, et al. Minimal residual disease monitoring with high-throughput sequencing of T‑cell receptors in cutaneous T‑cell lymphoma. Sci Transl Med. 2013;5(214):214ra171. CrossRefPubMed Weng WK, Armstrong R, Arai S, et al. Minimal residual disease monitoring with high-throughput sequencing of T‑cell receptors in cutaneous T‑cell lymphoma. Sci Transl Med. 2013;5(214):214ra171. CrossRefPubMed
5.
Zurück zum Zitat Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–5. PubMedPubMedCentral Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–5. PubMedPubMedCentral
6.
Zurück zum Zitat Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–66. CrossRefPubMed Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–66. CrossRefPubMed
7.
Zurück zum Zitat Rozati S, Kim YH. Experimental treatment strategies in primary cutaneous T‑cell lymphomas. Curr Opin Oncol. 2016;28(2):166–71. CrossRefPubMed Rozati S, Kim YH. Experimental treatment strategies in primary cutaneous T‑cell lymphomas. Curr Opin Oncol. 2016;28(2):166–71. CrossRefPubMed
8.
Zurück zum Zitat Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11(1):19–20. CrossRefPubMed Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11(1):19–20. CrossRefPubMed
9.
Zurück zum Zitat Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65. CrossRefPubMed Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65. CrossRefPubMed
10.
Zurück zum Zitat Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35. CrossRefPubMedPubMedCentral Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35. CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Duvic M, et al. Results of a phase II trial of brentuximab vedotin for CD30 + cutaneous T‑cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65. CrossRefPubMedPubMedCentral Duvic M, et al. Results of a phase II trial of brentuximab vedotin for CD30 + cutaneous T‑cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65. CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression levels: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8. CrossRefPubMedPubMedCentral Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression levels: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8. CrossRefPubMedPubMedCentral
Metadaten
Titel
Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
verfasst von
MD Sonja Burgstaller
Josef Thaler
Publikationsdatum
27.03.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0325-5